Brian Mueller - Feb 25, 2025 Form 4 Insider Report for BIOMARIN PHARMACEUTICAL INC (BMRN)

Role
EVP, Chief Financial Officer
Signature
/s/ Tae Sang Yoo, Attorney-in-Fact
Stock symbol
BMRN
Transactions as of
Feb 25, 2025
Transactions value $
$0
Form type
4
Date filed
2/27/2025, 07:19 PM
Previous filing
Jul 1, 2024
Next filing
Mar 18, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BMRN Common Stock Award $0 +11K +15.43% $0.00 82.6K Feb 25, 2025 Direct F1, F2, F3
transaction BMRN Common Stock Award $0 +9.66K +11.69% $0.00 92.3K Feb 25, 2025 Direct F1, F3, F4
transaction BMRN Common Stock Award $0 +9.37K +10.15% $0.00 102K Feb 25, 2025 Direct F1, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis.
F2 Represents the total number of RSUs earned pursuant to a formula based on relative total shareholder return during 2022 through 2024 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan.
F3 Although earned, the RSUs only vest according to the following schedule: vests on March 15, 2025, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events.
F4 Represents the total number of RSUs earned pursuant to a formula based on the number and nature of development goals achieved during 2022 through 2024 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan.
F5 Represents the total number of RSUs earned pursuant to a formula based on core operating margin over three, one-year periods spanning 2022 through 2024 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan.